Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2236799 | 0.91 | KCNH2 (0.61) | KCNH2OPRK1OPRM1OPRD1 | |
| Fumaric Acid SCHEMBL2236792 | 0.91 | KCNH2 (0.61) | KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL2241658 | 0.87 | OPRK1 (0.61) | KCNH2OPRK1OPRM1OPRD1DRD2 | |
| SCHEMBL2237513 | 0.87 | KCNH2 (0.64) | KCNH2OPRK1OPRM1OPRD1DRD2 | |
| SCHEMBL2236776 | 0.83 | KCNH2 (0.63) | KCNH2OPRK1OPRM1OPRD1DRD2 | |
| SCHEMBL2237496 | 0.83 | KCNH2 (0.47) | KCNH2OPRK1OPRM1OPRD1 | |
| Fumaric Acid SCHEMBL2239154 | 0.82 | KCNH2 (0.62) | KCNH2OPRK1OPRM1OPRD1 | |
| Fumaric Acid SCHEMBL2239163 | 0.82 | KCNH2 (0.62) | KCNH2OPRK1OPRM1OPRD1 | |
| Fumaric Acid SCHEMBL2236843 | 0.81 | KCNH2 (0.60) | KCNH2OPRK1OPRM1OPRD1 | |
| Fumaric Acid SCHEMBL2236834 | 0.81 | KCNH2 (0.60) | KCNH2OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713990-B2 | 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-05-11 | — | — | US | claimed |
| US-20080004252-A1 | 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-01-03 | — | — | US | claimed |
| EP-1838705-A2 | 3,8-SUBSTITUTED 8-AZA-BICYCLO [3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-10-03 | — | — | EP | claimed |
| WO-2006075004-A2 | 3, 8 - SUBSTITUTED 8-AZA-BICYCLO[3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | WO | claimed |
| US-7989470-B2 | 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-08-02 | — | — | US | disclosed |
| US-20100190821-A1 | 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-07-29 | — | — | US | disclosed |
| US-7713990-B2 | 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-05-11 | — | — | US | disclosed |
| US-20080004252-A1 | 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-01-03 | — | — | US | disclosed |
| EP-1838705-A2 | 3,8-SUBSTITUTED 8-AZA-BICYCLO [3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006075004-A2 | 3, 8 - SUBSTITUTED 8-AZA-BICYCLO[3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190821-A1 | 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | KCNH2 1080/4885OPRK1 185/4885OPRM1 87/4885 |
| US-20080004252-A1 | 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC18A3, SLC6A2 | KCNH2 1080/4885OPRK1 185/4885OPRM1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.